UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

Clinical cancer research, 2016-11, Vol.22 (22), p.5527-5538

2016

Volltextzugriff (PDF)

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

Journal of medicinal chemistry, 2016-05, Vol.59 (10), p.4948-4964

2016

Volltextzugriff (PDF)

Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients

Clinical cancer research, 2014-11, Vol.20 (22), p.5745-5755

2014

Volltextzugriff (PDF)

The scavenger receptor MARCO is required for lung defense against pneumococcal pneumonia and inhaled particles

The Journal of experimental medicine, 2004-07, Vol.200 (2), p.267-272

2004

Volltextzugriff (PDF)

Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen

Chemical biology & drug design, 2011-12, Vol.78 (6), p.999-1005

2011

Volltextzugriff (PDF)

The Macrophage Scavenger Receptor SR-AI/II and Lung Defense against Pneumococci and Particles

American journal of respiratory cell and molecular biology, 2006-10, Vol.35 (4), p.474-478

2006

Volltextzugriff (PDF)

Alveolar macrophage cytokine response to air pollution particles: Oxidant mechanisms

Toxicology and applied pharmacology, 2007-02, Vol.218 (3), p.256-264

2007

Volltextzugriff (PDF)

Abstract 2644: AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2644-2644

2016

Volltextzugriff (PDF)

9-(Arenethenyl)purines as Dual Src/Abl Kinase Inhibitors Targeting the Inactive Conformation: Design, Synthesis, and Biological Evaluation

Journal of medicinal chemistry, 2009-08, Vol.52 (15), p.4743-4756

2009

Volltextzugriff (PDF)

Insoluble Components of Concentrated Air Particles Mediate Alveolar Macrophage Responses in Vitro

Toxicology and applied pharmacology, 2000-09, Vol.167 (2), p.140-150

2000

Volltextzugriff (PDF)

Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR–ABL including the T315I gatekeeper mutant

Bioorganic & medicinal chemistry letters, 2011-06, Vol.21 (12), p.3743-3748

2011

Volltextzugriff (PDF)

ALVEOLAR MACROPHAGE CYTOKINE PRODUCTION IN RESPONSE TO AIR PARTICLES IN VITRO: ROLE OF ENDOTOXIN

Journal of Toxicology and Environmental Health, Part A, 2000-02, Vol.59 (3), p.165-180

Yaoyu Ning, Amy Imrich, Carroll-Ann Goldsmith, Guozhong Qin, Lester Kobzik

2000

Volltextzugriff (PDF)

Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer

Cancer discovery, 2021-07, Vol.11 (7), p.1672-1687

2021

Volltextzugriff (PDF)

EFFECTS OF ENVIRONMENTAL AEROSOLS ON AIRWAY HYPERRESPONSIVENESS IN A MURINE MODEL OF ASTHMA

Inhalation toxicology, 1999-11, Vol.11 (11), p.981-998

1999

Volltextzugriff (PDF)

Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors

Bioorganic & medicinal chemistry letters, 2008-09, Vol.18 (17), p.4907-4912

2008

Volltextzugriff (PDF)

Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non–small cell lung cancer

Bioorganic & medicinal chemistry letters, 2023-01, Vol.80, p.129084-129084, Article 129084

2023

Volltextzugriff (PDF)

Potent Preclinical Activity of Ponatinib in Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma (GCB-DLBCL) Models

Blood, 2015-12, Vol.126 (23), p.4000-4000

2015

Volltextzugriff (PDF)

Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens

Molecular cancer therapeutics, 2011-06, Vol.10 (6), p.1059-1071

2011

Volltextzugriff (PDF)

Particle-Epithelial Interaction: Effect of Priming and Bystander Neutrophils on Interleukin-8 Release

American journal of respiratory cell and molecular biology, 2004-05, Vol.30 (5), p.744-750

2004

Volltextzugriff (PDF)

Stromelysin-3 Is Induced in Tumor/Stroma Cocultures and Inactivated via a Tumor-specific and Basic Fibroblast Growth Factor-dependent Mechanism

The Journal of biological chemistry, 1998-01, Vol.273 (1), p.618-626

1998

Volltextzugriff (PDF)

Inhibition of aflatoxin B1-induced initiation of hepatocarcinogenesis in the rat by green tea

Cancer letters, 1997-01, Vol.112 (2), p.149-154

1997

Volltextzugriff (PDF)

Chemoprevention of Aflatoxin B1-Initiated and Carbon Tetrachloride-Promoted Hepatocarcinogenesis in the Rat by Green Tea

Nutrition and cancer, 2000, Vol.38 (2), p.215-222

2000

Volltextzugriff (PDF)

Abstract 2827: Discovery of AP26113, a potent, orally active inhibitor of anaplastic lymphoma kinase and clinically relevant mutants

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.2827-2827

2015

Volltextzugriff (PDF)

A Pilot Investigation of the Relative Toxicity of Indoor and Outdoor Fine Particles: In Vitro Effects of Endotoxin and Other Particulate Properties

Environmental health perspectives, 2001-10, Vol.109 (10), p.1019-1026

2001

Volltextzugriff (PDF)

1 – 25 von 72

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(67)
Mit Volltextzugriff
(68)

Publikationsform

Sprache

Englisch
(69)
Chinesisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(46)
Life Sciences & Biomedicine
(38)
Animals
(32)
Humans
(21)
Female
(17)
Mice
(17)
Biological And Medical Sciences
(14)
Male
(13)
Rats
(12)
Medical Sciences
(10)
China
(8)
Mutation
(8)
Oncology
(8)
Protein Kinase Inhibitors - Pharmacology
(8)
Cell Line, Tumor
(7)
Pharmacology & Pharmacy
(7)
Antineoplastic Agents - Pharmacology
(6)
Biochemistry & Molecular Biology
(6)
General Aspects
(6)
Macrophages, Alveolar - Metabolism
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients

The scavenger receptor MARCO is required for lung defense against pneumococcal pneumonia and inhaled particles

Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen

The Macrophage Scavenger Receptor SR-AI/II and Lung Defense against Pneumococci and Particles

Alveolar macrophage cytokine response to air pollution particles: Oxidant mechanisms

Abstract 2644: AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models

9-(Arenethenyl)purines as Dual Src/Abl Kinase Inhibitors Targeting the Inactive Conformation: Design, Synthesis, and Biological Evaluation

Insoluble Components of Concentrated Air Particles Mediate Alveolar Macrophage Responses in Vitro

Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR–ABL including the T315I gatekeeper mutant

ALVEOLAR MACROPHAGE CYTOKINE PRODUCTION IN RESPONSE TO AIR PARTICLES IN VITRO: ROLE OF ENDOTOXIN

Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer

EFFECTS OF ENVIRONMENTAL AEROSOLS ON AIRWAY HYPERRESPONSIVENESS IN A MURINE MODEL OF ASTHMA

Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors

Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non–small cell lung cancer

Potent Preclinical Activity of Ponatinib in Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma (GCB-DLBCL) Models

Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens

Particle-Epithelial Interaction: Effect of Priming and Bystander Neutrophils on Interleukin-8 Release

Stromelysin-3 Is Induced in Tumor/Stroma Cocultures and Inactivated via a Tumor-specific and Basic Fibroblast Growth Factor-dependent Mechanism

Inhibition of aflatoxin B1-induced initiation of hepatocarcinogenesis in the rat by green tea

Chemoprevention of Aflatoxin B1-Initiated and Carbon Tetrachloride-Promoted Hepatocarcinogenesis in the Rat by Green Tea

Abstract 2827: Discovery of AP26113, a potent, orally active inhibitor of anaplastic lymphoma kinase and clinically relevant mutants

A Pilot Investigation of the Relative Toxicity of Indoor and Outdoor Fine Particles: In Vitro Effects of Endotoxin and Other Particulate Properties

Suchergebnisse filtern